Cocrystal Pharma 2022 Antiviral Drug Pipeline Presentation

Cocrystal Pharma presents its potent antiviral drug discovery platform targeting pandemic coronaviruses, influenza A, and norovirus. The company leverages proprietary technology and a Merck collaboration to develop broad-spectrum antivirals effective against emerging variants and drug-resistant viruses, with key milestones including preclinical lead selection for oral protease inhibitors and IND-enabling studies planned for H1 2022.